Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Yartemlea Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0298

    Yartemlea (narsoplimab-wuug)

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0298 alerts

    Get alerted when Policy CC-0298 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization review of Yartemlea (narsoplimab-wuug) for members with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Coverage is limited to individuals meeting the specified diagnosis, age, laboratory, renal, and exclusion-of-alternative-etiology criteria.

    Policy Summary
    PayerEmpire Bluecross
    PolicyYartemlea (narsoplimab-wuug)
    Policy CodePolicy CC-0298
    Change TypeModified
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization requests with documentation supporting all diagnosis, age, laboratory, renal, and alternative-etiology criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was revised to update the criteria describing when Yartemlea may not be approved.

    HCPCS codes C9399 and J3590 were removed from the coding section.

    HCPCS code J1289 was added for injection of narsoplimab-wuug, 1 mg.

    Age 2+Minimum age criterion
    <150 x 10^9/LRequired platelet count
    2x baselineSerum-creatinine criterion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4–8 weeks
    Clinical trial duration
    8 dosesMedian clinical-trial doses
    J1289HCPCS code

    Coverage Criteria

    Initial Yartemlea therapy

    Requests for Yartemlea (narsoplimab-wuug) may be approved when ALL of the following criteria are met:

    ALL of the following

    • Individual has a diagnosis of persistent hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
    • Individual is 2 years of age and older.
    • ALL of the following (Khaled 2022)

      • Platelet count of less than 150 x 10 9 /L.
      • Evidence of microangiopathic hemolysis.
      • Evidence of renal dysfunction defined as a doubling of serum creatinine from pretransplant.
      • Alternative etiologies for thrombocytopenia and anemia have been ruled out.

    Yartemlea (narsoplimab-wuug) may not be approved for all other indications.

    Yartemlea (narsoplimab-wuug) may not be approved when any of the above criteria are not met.

    Coding and Clinical Thresholds

    HCPCSHCPCS
    J1289Injection, narsoplimab-wuug, 1 mg [Yartemlea]
    ICD-10 DiagnosisICD-10
    M31.11Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCTTMA]
    Platelet Count
    Required platelet countLess than 150 x 10^9/L
    Clinical findingThrombocytopenia
    Coverage requirementThe platelet-count criterion must be met along with all other listed criteria.
    Serum Creatinine
    Required renal findingEvidence of renal dysfunction
    Serum creatinine thresholdDoubling from the pretransplant level
    Coverage requirement

    Provider Actions and Review Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization and clinical review are required when Yartemlea is reviewed under the member’s medical benefit or is otherwise subject to clinical review. Coverage is evaluated against the policy’s medical-necessity criteria for the intended or prescribed use.

    Documentation Required

    Clinical Criteria Support

    Submit documentation supporting persistent hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and confirm that the individual is at least 2 years of age. Documentation must also establish all required clinical findings and exclusions.

    • Diagnosis of persistent HSCT-associated TA-TMA.
    • Individual is 2 years of age or older.
    • Platelet count is less than 150 × 109/L.
    • Evidence of microangiopathic hemolysis.

    Clinical Background

    HSCT-associated thrombotic microangiopathy (HSCT-TMA or TA-TMA) is a rare, severe, and often fatal complication of hematopoietic stem cell transplantation. It is caused by endothelial cell damage associated with transplant-related therapies, infection, graft-versus-host disease, and other factors, and may occur after either autologous or allogeneic transplantation. The resulting microvascular injury can present in a clinically serious transplant setting with thrombocytopenia, microangiopathic hemolysis, and renal dysfunction.

    Key Definition

    HSCT-TMA or TA-TMA
    ConditionA severe and often fatal complication of hematopoietic stem cell transplantation
    Underlying mechanismCaused by endothelial cell damage
    Associated factorsMay be triggered by therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation.

    Initial Therapy

    Initial Therapy Criteria

    Requests for Yartemlea may be approved if all of the following criteria are met:

    All initial-therapy criteria

    • The individual has persistent hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
    • The individual is 2 years of age or older.Age ≥2 years
    • Required clinical findings

      • Platelet count is less than 150 x 10^9/L.<150 x 10^9/L
    Policy Summary
    PayerEmpire Bluecross
    PolicyYartemlea (narsoplimab-wuug)
    Policy CodePolicy CC-0298
    Change TypeModified
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization requests with documentation supporting all diagnosis, age, laboratory, renal, and alternative-etiology criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Review RequirementsClinical BackgroundKey DefinitionInitial Therapy
    The renal criterion must be met along with all other listed criteria.
    Age
    Minimum age2 years
    Age requirementThe individual must be 2 years of age or older.
    Coverage requirementThe age criterion must be met along with all other listed criteria.
  1. Renal dysfunction demonstrated by doubling of serum creatinine from pretransplant.
  2. Alternative etiologies for thrombocytopenia and anemia have been ruled out.
  3. Clinical criteria are based on Khaled 2022.
  4. Denial Risk

    Failure to Meet Clinical Criteria

    Requests may be denied when the required criteria are not met. The individual must satisfy the diagnosis, age, laboratory, hemolysis, renal dysfunction, and alternative-etiology exclusion requirements.

    • Failure to document persistent HSCT-associated TA-TMA or age of at least 2 years may result in denial.
    • Failure to meet the platelet count, microangiopathic hemolysis, or serum creatinine criteria may result in denial.
    • Failure to rule out alternative causes of thrombocytopenia and anemia may result in denial.
    Denial Risk

    Non-Covered Indications

    Yartemlea may not be approved for indications outside the policy-defined condition of persistent HSCT-associated thrombotic microangiopathy, including all other indications.

    • Coverage is limited to the policy-defined indication: persistent HSCT-associated TA-TMA.
    There is evidence of microangiopathic hemolysis.
  5. There is evidence of renal dysfunction defined as a doubling of serum creatinine from pretransplant.2x pretransplant serum creatinine
  6. Alternative etiologies for thrombocytopenia and anemia have been ruled out.